News
Kamada Tests Inhaled Alpha-1 Protein for Bronchiectasis
Israeli bio biopharmaceutical company Kamada will soon start phase II clinical trials with the inhaled version of its Alpha-1 Antitrypsin (AAT) product to treat Bronchiectasis, a lung disease that results in the distortion of one or more of the conducting bronchi or airways, most often secondary to an infectious process.
The study will be conducted using an eFlow® Electronic Nebulizer optimized for delivery of Kamada’s AAT product.
